FdaApplication
NDA 217439
Identifiers
- fda_app_no: NDA217439
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2024-03-07 |
Revenue by product
TALZENNA
| Period | Revenue |
|---|---|
| Q2 2026 | $57.0M |
| Q1 2026 | $50.0M |
| Q3 2025 | $47.0M |
| Q2 2025 | $46.0M |
| Q1 2025 | $40.0M |
| Q3 2024 | $36.0M |
| Q2 2024 | $32.0M |
| Q1 2024 | $23.0M |
| Q3 2023 | $20.0M |
| Q2 2023 | $12.0M |
| Q1 2023 | $10.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TALZENNA | TALAZOPARIB TOSYLATE | EQ 0.35MG BASE | CAPSULE;ORAL |
| TALZENNA | TALAZOPARIB TOSYLATE | EQ 1MG BASE | CAPSULE;ORAL |
| TALZENNA | TALAZOPARIB TOSYLATE | EQ 0.1MG BASE | CAPSULE;ORAL |
| TALZENNA | TALAZOPARIB TOSYLATE | EQ 0.5MG BASE | CAPSULE;ORAL |
| TALZENNA | TALAZOPARIB TOSYLATE | EQ 0.25MG BASE | CAPSULE;ORAL |
| TALZENNA | TALAZOPARIB TOSYLATE | EQ 0.75MG BASE | CAPSULE;ORAL |
6 products